Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601372 | 0.82 | PROKR1 (0.52) | HRH3KDM4EKCNH2 | |
| SCHEMBL17350547 | 0.78 | HSD11B1 (0.51) | HRH3KDM4EHSD11B1 | |
| SCHEMBL599542 | 0.77 | HRH3 (0.50) | HRH3KDM4EKCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL599177 | 0.76 | KDM4E (0.59) | HRH3KDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL599543 | 0.76 | HRH3 (0.55) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL7893397 | 0.76 | L3MBTL3 (0.55) | HRH3KDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL3709924 | 0.76 | HRH3 (0.57) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL17350856 | 0.76 | HPGD (0.52) | KDM4EHSD11B1 | |
| SCHEMBL599318 | 0.75 | HPGD (0.47) | HRH3KCNH2HSD11B1 | |
| SCHEMBL599001 | 0.74 | HRH3 (0.52) | HRH3KDM4EKCNH2L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | claimed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| WO-2010086403-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH3, HRH2, HRH1 | HRH3 1/4885KDM4E 697/4885KCNH2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.